PRCT Stock Analysis: Procept Biorobotics | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.161m USD | 12M Return: -21.8% | US74276L1052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 23.8M
Qual. Beats: 0
Rev. Trend: 97.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.2 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Procept BioRobotics Corporation (NASDAQ: PRCT) is a surgical robotics company that develops, manufactures, and sells image-guided robotic systems for urology, operating in the United States and select international markets. Its core product, the AquaBeam Robotic System, performs minimally invasive urologic surgery for the treatment of benign prostatic hyperplasia (BPH), a common non-cancerous enlargement of the prostate affecting older men. The company also offers the HYDROS Robotic System, which delivers Aquablation therapy for men suffering from lower urinary tract symptoms associated with BPH. The company was incorporated in 2007 and is headquartered in San Jose, California.
Classified within the Health Care Equipment sub-industry, PRCT operates in the medical device sector with a focused, single-therapeutic-area business model centered on urological robotics. The company went public in September 2021 and is currently positioned as a small-cap stock, reflecting its relatively narrow product portfolio and early commercial stage compared to larger, diversified medical device peers.
- U.S. Aquablation adoption accelerates hospital procedure volume
- HYDROS system launch drives recurring razor-and-blade revenue growth
- Reimbursement expansion broadens benign prostatic hyperplasia market access
- Competition from Rezūm and other BPH therapies pressures market share
- Operating margin improvement lags as commercial spending scales with installed base
| Net Income: -114.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA -2.37 > 1.0 |
| NWC/Revenue: 97.60% < 20% (prev 133.5%; Δ -35.88% < -1%) |
| CFO/TA -0.16 > 3% & CFO -76.7m > Net Income -114.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.8m) vs 12m ago 25.22% < -2% |
| Gross Margin: 64.66% > 18% (prev 63.48%; Δ 1.18% > 0.5%) |
| Asset Turnover: 71.51% > 50% (prev 58.63%; Δ 12.88% > 0%) |
| Interest Coverage Ratio: -34.73 > 6 (EBIT TTM -118.4m / Interest Expense TTM 3.41m) |
| A: 0.73 (Total Current Assets 414.2m - Total Current Liabilities 70.4m) / Total Assets 473.8m |
| B: -1.53 (Retained Earnings -726.6m / Total Assets 473.8m) |
| C: -0.24 (EBIT TTM -118.4m / Avg Total Assets 492.6m) |
| D: 2.27 (Book Value of Equity 328.9m / Total Liabilities 144.9m) |
| Altman-Z'' = 0.53 = B |
| DSRI: 1.06 (Receivables 105.0m/84.5m, Revenue 352.3m/299.9m) |
| GMI: 0.98 (GM 63.48% / 64.66%) |
| AQI: 1.50 (AQ_t 0.03 / AQ_t-1 0.02) |
| SGI: 1.17 (Revenue 352.3m / 299.9m) |
| TATA: -0.08 (NI -114.9m - CFO -76.7m) / TA 473.8m) |
| Beneish M = -2.58 (Cap -4..+1) = A |
As of November 16, 2026, the stock is trading at USD 23.80 with a total of 1,677,806 shares traded. Over the past week, the price has changed by +15.42%, over one month by +24.61%, over three months by +8.43% and over the past year by -21.76%.
Current recommended Stop Loss: 22.00 (which is 7.6% or 1.3 ATR below the current price).
Procept Biorobotics has received a consensus analysts rating of 3.47. Therefore, it is recommended to hold PRCT.
- StrongBuy: 3
- Buy: 2
- Hold: 9
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 22.3 | -6.5% |
P/S = 3.4201
P/B = 3.5458
Revenue TTM = 352.3m USD
EBIT TTM = -118.4m USD
EBITDA TTM = -112.0m USD
Long Term Debt = 51.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.21m USD (from shortTermDebt, last fiscal year)
Debt = 77.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 25.8m
Net Debt = -140.8m USD (calculated: Debt 77.6m - CCE 218.4m)
Enterprise Value = 1.02b USD (1.16b + Debt 77.6m - CCE 218.4m)
Interest Coverage Ratio = -34.73 (Ebit TTM -118.4m / Interest Expense TTM 3.41m)
EV/FCF = -11.99x (Enterprise Value 1.02b / FCF TTM -85.1m)
FCF Yield = -8.34% (FCF TTM -85.1m / Enterprise Value 1.02b)
FCF Margin = -24.15% (FCF TTM -85.1m / Revenue TTM 352.3m)
Net Margin = -32.60% (Net Income TTM -114.9m / Revenue TTM 352.3m)
Gross Margin = 64.66% ((Revenue TTM 352.3m - Cost of Revenue TTM 124.5m) / Revenue TTM)
Gross Margin QoQ = 66.28% (prev 66.01%)
Tobins Q-Ratio = 2.15 (Enterprise Value 1.02b / Total Assets 473.8m)
Interest Expense / Debt = 4.40% (Interest Expense 3.41m / Debt 77.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -93.5m (EBIT -118.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.89 (Total Current Assets 414.2m / Total Current Liabilities 70.4m)
Debt / Equity = 0.24 (Debt 77.6m / totalStockholderEquity, last quarter 328.9m)
Debt / EBITDA = 1.26 (negative EBITDA) (Net Debt -140.8m / EBITDA -112.0m)
Debt / FCF = 1.66 (negative FCF - burning cash) (Net Debt -140.8m / FCF TTM -85.1m)
Total Stockholder Equity = 345.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.31% (Net Income -114.9m / Total Assets 473.8m)
RoE = -33.23% (Net Income TTM -114.9m / Total Stockholder Equity 345.6m)
RoCE = -29.81% (EBIT -118.4m / Capital Employed (Equity 345.6m + L.T.Debt 51.6m))
RoIC = -24.11% (negative operating profit) (NOPAT -93.5m / Invested Capital 388.0m)
WACC = 8.12% (E(1.16b)/V(1.24b) * Re(8.43%) + D(77.6m)/V(1.24b) * Rd(4.40%) * (1-Tc(0.21)))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.77 | Cagr: 14.33%
[DCF] Fair Price = unknown (Cash Flow -85.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.77 | # QB: 0
Revenue Correlation: 97.76 | Revenue CAGR: 41.29% | SUE: -0.29 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.38 | Chg30d=-1.80% | Revisions=-50% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.68 | Chg30d=-0.10% | Revisions=-77% | GrowthEPS=+2.2% | GrowthRev=+28.3%
EPS next Year (2027-12-31): EPS=-1.17 | Chg30d=-1.63% | Revisions=+25% | GrowthEPS=+30.3% | GrowthRev=+20.5%
[Analyst] Revisions Ratio: -67% (up=2, down=16)